Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2009
10/29/2009WO2009131264A1 Method for preparing ortho-dihydroxyisoflavones using a biotransformation system
10/29/2009WO2009131245A1 Iminopyridine derivatives and use thereof
10/29/2009WO2009131216A1 Lipid membrane structure modified with oligo(alkylene glycol)
10/29/2009WO2009131201A1 Therapeutic agent for intermittent claudication
10/29/2009WO2009131200A1 Therapeutic agent for irritable bowel syndrome
10/29/2009WO2009131196A1 Substituted pyrrolidine derivative and use thereof
10/29/2009WO2009131173A1 2-aminoquinazoline derivative
10/29/2009WO2009131171A1 Novel five-membered ring compound
10/29/2009WO2009131170A1 Five-membered ring compound
10/29/2009WO2009131166A1 Wnt signaling inhibitor comprising insulin-like growth factor-binding protein
10/29/2009WO2009131164A1 Eye-drop preparation and use thereof
10/29/2009WO2009131135A1 Iminopyridine derivative and use thereof
10/29/2009WO2009131129A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009WO2009131127A1 5-hydroxypyrimidine-4-carboxamide compound
10/29/2009WO2009131098A1 Method of utilization of combination of benzophenone derivative or salt thereof and immunosuppressing agent, and pharmaceutical composition comprising these components
10/29/2009WO2009131096A1 Compound having npy y5 receptor antagonist activity
10/29/2009WO2009131090A1 Amino acid compound
10/29/2009WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient
10/29/2009WO2009130735A1 Fatty acid derivatives for oral administration endowed with high palatability
10/29/2009WO2009130715A1 Rapidly disintegrating oral compositions of tramadol
10/29/2009WO2009130712A2 Controlled release pharmaceutical compositions of trospium
10/29/2009WO2009130679A1 Benzimidazole derivatives as calcium channel blockers
10/29/2009WO2009130616A2 Improved tlr3 agonist compositions
10/29/2009WO2009130560A1 Fused pyrimidineone compounds as trpv3 modulators
10/29/2009WO2009130496A1 Substituted pyrimidin-5-carboxamides 281
10/29/2009WO2009130487A1 Aryl-quinolyl compounds and their use
10/29/2009WO2009130475A1 Substituted thiophenecarboxamides as ikk-beta serine-, threonine-protein kinase inhibitors
10/29/2009WO2009130469A1 Dna-pk inhibitors
10/29/2009WO2009130453A1 Inhibitors of plk
10/29/2009WO2009130434A1 INHIBITORS OF IKK-β SERINE-THREONINE PROTEIN KINASE
10/29/2009WO2009130422A2 N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway
10/29/2009WO2009130344A1 Personalised pharmaceutical composition containing retinoic acid, for anti-aging of the skin
10/29/2009WO2009130342A1 Improved pharmaceutical composition containing ibuprofen and codeine
10/29/2009WO2009130331A1 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors
10/29/2009WO2009130326A1 Combination therapy for acne vulgaris comprising adapalene 0.3% gel with clindamycin/benzoyl peroxide gel
10/29/2009WO2009130317A1 1- (7-(hexahydropyrrolo [3, 4-c] pyrrol-2 (1h) -yl) quin0lin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (gsk-3)
10/29/2009WO2009130310A1 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof
10/29/2009WO2009130289A1 HYDROGENSULFATE SALT OF 2-ACETOXY-5-(a-CYCLOPROPYLCARBONYL-2-FLUOROBENZYL)-4,5,6,7-TETRAHYDROTHIENO[3,2-c]PYRIDINE AND ITS PREPARATION
10/29/2009WO2009130272A1 Nalmefene prodrugs
10/29/2009WO2009130270A1 Nalmefene di-ester prodrugs
10/29/2009WO2009130264A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE
10/29/2009WO2009130263A1 PROCESS FOR PREPARING A CRYSTALLINE FORM COMPOUND OF 3-BENZYL-2-METHYL-2,3,3a,4,5,6,7,7a-OCTAHYDROBENZO[d]ISOXAZOL-4-ONE
10/29/2009WO2009130253A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases
10/29/2009WO2009130242A1 Low molecular weight derivatives and use thereof in treatment of prostaglandin e synthase related diseases
10/29/2009WO2009130240A1 Isoquinolinone derivatives as nk3 antagonists
10/29/2009WO2009130234A1 (5r)-1,5-diaryl-4,5-dihydro-1h-pyrazole-3-carboxamidine derivatives having cb1-antagonistic activity
10/29/2009WO2009130232A1 Pyrazolo [1, 5 -a] pyrazine derivatives as antagonists of v1b receptors
10/29/2009WO2009130231A1 Pyrrolo [1, 2-a] pyrazine derivatives as vasopressin vib receptor antagonists
10/29/2009WO2009130204A2 Improved formulations for poorly permeable active pharmaceutical ingredients
10/29/2009WO2009130189A1 2'-o,3'-n-bridged macrolides
10/29/2009WO2009130039A1 Transdermal therapeutic system for administration of fentanyl or an analog thereof
10/29/2009WO2009130016A1 Dihydropteridinones as plk inhibitors
10/29/2009WO2009130015A1 Improved raf inhibitors
10/29/2009WO2009129983A1 Acid addition salts of prasugrel and pharmaceutical compositions comprising the same
10/29/2009WO2009129945A1 Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
10/29/2009WO2009129938A1 Substituted phenoxybenzamides
10/29/2009WO2009129927A1 Compositions for the treatment of vaginal infections with chronic inflammation
10/29/2009WO2009129926A1 Compositions for the treatment and prevention of infections of the oral cavity
10/29/2009WO2009129913A1 Solid pharmaceutical preparation comprising 1-[(4-chloro-phenyl)-amide]-2-{[4-(3-oxo-morpholine-4-yl)-phenyl]-amide}-4-hydroxy-pyrrolidine-1,2-dicarboxylic acid
10/29/2009WO2009129905A1 Pyridazinone derivatives
10/29/2009WO2009129859A1 Compositions and methods for maintaining, strengthening, improving, or promoting eye health
10/29/2009WO2009129798A2 Diphosphate and triphosphate prodrugs, in particular nucleoside diphosphate and triphosphate prodrugs
10/29/2009WO2009129726A1 Nitrone compounds, process of preparation thereof, and use thereof in medicament manufacture
10/29/2009WO2009129696A1 A kind of receptor signaling transoluction positive modulators, preparation methods and uses thereof
10/29/2009WO2009129694A1 A new micelle formulation compriseing prostaglandin e1 entrapmented by polyglycol-derived phospholipid
10/29/2009WO2009129630A1 Covalently grafted pharmaceutically active polymers
10/29/2009WO2009129627A1 Novel resveratrol compositions
10/29/2009WO2009129625A1 Novel substituted heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
10/29/2009WO2009129592A1 Liquid formulation for deferiprone with palatable taste
10/29/2009WO2009111658A3 Compositions and methods for inhibiting expression of eg5 and vegf genes
10/29/2009WO2009111574A3 BISMETHYLENE-17α CARBOLACTONES AND RELATED USES
10/29/2009WO2009111375A3 Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
10/29/2009WO2009111078A3 Combination of a ppary agonist and a dipeptidyl peptidase-inhibitor for the treatment of diabetes and obesity
10/29/2009WO2009110942A3 Generation of combinatorial synthetic libraries and screening for novel proadhesins and nonadhesins
10/29/2009WO2009110938A3 Novel macrocyclic polyene lactams
10/29/2009WO2009109524A4 Superabsorbent composition with metal salicylate for odour control
10/29/2009WO2009109493A3 2-aminoquinoline derivatives as 5-ht ( 5a) receptor antagonists
10/29/2009WO2009107933A3 Pharmaceutical compositions for inhibiting angiogenesis
10/29/2009WO2009106980A3 Indazole derivatives
10/29/2009WO2009106831A3 Pharmaceutical composition comprising naltrexone
10/29/2009WO2009106640A3 N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
10/29/2009WO2009105504A3 Functionally selective alpha2c adrenoreceptor agonists
10/29/2009WO2009104911A3 Uses as agents for prophylaxis or treatment of cervical cancer
10/29/2009WO2009103932A8 Use of a cardiac glycoside and/or a diuretic for the treatment of neuropathic pain
10/29/2009WO2009103808A3 Methods and compositions for increasing rna interference
10/29/2009WO2009103534A3 Elansolids, novel natural metabolites of flexibacter and antibiotically active derivatives thereof
10/29/2009WO2009102789A3 Use of rxr agonists for the treatment of osteroarthritis
10/29/2009WO2009102465A3 Continuous cell programming devices
10/29/2009WO2009099628A3 Compositions and methods for influencing recovery from strenuous physical activity
10/29/2009WO2009097567A4 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands
10/29/2009WO2009093880A3 Treatment and prevention of cardiac conditions using two or more isoforms of hepatocyte growth factor
10/29/2009WO2009093208A3 Substituted 2-amino-3-sulfonyl-pyrazolo[1,5-a] pyrimidines/antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009093206A3 3-sulfonyl-pyrazolo[1,5-a] pyrimidines / antagonists of serotonin 5-ht6 receptors, methods for the production and the use thereof
10/29/2009WO2009087568A3 Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties
10/29/2009WO2009084041A3 Pharmaceutical compositions of dexibuprofen
10/29/2009WO2009083643A3 Composition for treating sterile inflammation
10/29/2009WO2009075870A9 Compounds and methods for the treatment of cancer
10/29/2009WO2009075607A3 Pharmaceutical preparation comprising stephaglabrin sulfate for treating demyelinating diseases of the nervous system and for promoting restoration of the myelin sheath of nerve fibers
10/29/2009WO2009068922A3 Compositions containing capsaicinoids
10/29/2009WO2009065022A3 Low density lipoprotein receptor-mediated sirna delivery
1 ... 2518 2519 2520 2521 2522 2523 2524 2525 2526 2527 2528 2529 2530 2531 2532 2533 2534 2535 2536 2537 2538 ... 7860